Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

FDA Drug Recalls

1,525 recalls · Class III, newest first

Class III · Low risk

Lorazepam

Labeling: Incorrect or Missing Lot and/or Exp Date: Lorazepam Lot # L-04009

Terminated Labeling / mix-up Legacy Pharmaceutical Packaging LLC NDC 0904-6007-60 D-580-2013
Class III · Low risk

Disulfiram Tablets USP 250 mg

CGMP Deviation; cotton coil is missing in some packaged bottles

Terminated cGMP deviation Teva Pharmaceuticals USA, Inc. NDC 0093-5035-01 D-578-2013
Class III · Low risk

Tizanidine Tablets USP

Labeling Illegible: There is a possibility that the bottle labels do not contain the strength of the product as well as other printing details.

Terminated Labeling / mix-up Dr. Reddy'S Laboratories NDC 55111-180-15 D-238-2013
Class III · Low risk

Camila 0.35 mg Tablets

Failed Impurity/Degradation Specification; an impurity identified as N-Butyl-Benzene Sulfonamide (NBBS) was detected during impurity testing

Terminated Chemical / undeclared Physicians Total Care, Inc. NDC 54868-4814-0 D-499-2013
Class III · Low risk

Oxcarbazepine Tablets

SubPotent Drug: The firm discovered out of specification results for assay and the extended investigation revealed the potential for lower weight tablets.

Terminated Wrong potency / content Boehringer Ingelheim Roxane Inc NDC 0054-0097-20 D-343-2014
Class III · Low risk

Camila (norethindrone tablets, USP)

Failed Impurity/Degradation Specification; an impurity identified as N-Butyl-Benzene Sulfonamide (NBBS) was detected during impurity testing

Terminated Chemical / undeclared Teva Pharmaceuticals USA, Inc. NDC 0555-0715-58 D-690-2013
Class III · Low risk

Errin (norethindrone tablets, USP)

Failed Impurity/Degradation Specification; an impurity identified as N-Butyl-Benzene Sulfonamide (NBBS) was detected during impurity testing

Terminated Chemical / undeclared Teva Pharmaceuticals USA, Inc. NDC 0555-0344-58 D-689-2013
Class III · Low risk

Junel

Failed Impurity/Degradation Specification; an impurity identified as N-Butyl-Benzene Sulfonamide (NBBS) was detected during impurity testing

Terminated Chemical / undeclared Teva Pharmaceuticals USA, Inc. NDC 0555-9028-58 D-682-2013
Class III · Low risk

Acetic Acid Otic Solution

Subpotent Drug: The product/lot is out-of-specification (OOS) for the assay of acetic acid at the 18-month test station.

Terminated Wrong potency / content Hi-Tech Pharmacal Co., Inc. NDC 50383-889-15 D-302-2013
Class III · Low risk

Nupercainal

Labeling: Incorrect or Missing Lot and/or Exp Date. The lot number and/or expiration date may be illegible.

Terminated Labeling / mix-up Novartis Consumer Health NDC 0067-5812-96 D-208-2013
Class III · Low risk

Myoflex (trolamine salicylate)

Labeling: Incorrect or Missing Lot and/or Exp Date. The lot number and/or expiration date may be illegible.

Terminated Labeling / mix-up Novartis Consumer Health D-207-2013
Class III · Low risk

Voltaren 1% Gel

Labeling: Incorrect or Missing Lot and/or Expiration Date; This recall is being initiated because the lot number and expiration date on the tube may not be legible.

Terminated Labeling / mix-up Physicians Total Care, Inc. NDC 54868-5965-00 D-596-2013

Recalls by year